skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Reducing morbidity and mortality in high risk patients with statins

Review

(3381) Views  (1084) Full article downloads

Authors: Vibhuti Singh, Prakash Deedwania

Published Date June 2009 Volume 2009:5 Pages 495 - 507
DOI: http://dx.doi.org/10.2147/VHRM.S3389

Vibhuti Singh1, Prakash Deedwania2

1University of South Florida College of Medicine, and Suncoast Cardiovascular Center, St. Petersburg, Florida, USA; 2Cardiology Division, VACCHCS/UCSF, Fresno, CA, and UCSF School of Medicine, San Francisco, CA, USA

Abstract: Residual coronary heart disease remains a significant problem even after adequate statin therapy for cardiovascular risk reduction as currently recommended by the Adult Treatment Panel III (ATP-III) of the National Cholesterol Education Program (NCEP). This is particularly true for the high risk patients as defined by ATP-III that includes those patients who have a greater than 20% 10-year risk of adverse cardiac events. For such patients the current goal of a low-density lipoprotein cholesterol (LDL-cholesterol) maintenance level of ≤100 mg/dL plasma appears to be suboptimal. Accumulating data from several recent randomized studies of more aggressive LDL-cholesterol reduction to levels below 70 mg/dL in the high risk patients favor acceptance of such a new lower target for LDL-cholesterol using more intensive statin therapy which would affect the treatment strategy for patients with coronary heart disease pre-percutaneous intervention, metabolic syndrome, diabetes mellitus, congestive heart failure, cerebro-vascular disease and chronic kidney disease.

Keywords: statins, high risk patients, dyslipidemia, intensive statin therapy, metabolic syndrome, diabetes, congestive heart failure, chronic kidney disease, coronary atherosclerosis, pre-percutaneous intervention






 

Other articles by Dr Prakash Deedwania



Readers of this article also read:

Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk
Coronary computed tomographic angiography (CCTA) in community hospitals: “current and emerging role”
Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia
Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits
Current state of cardiac rehabilitation in Germany: patient characteristics, risk factor management and control status, by education level
Barriers to cardiovascular risk prevention and management in Germany – an analysis of the EURIKA study
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University